VivoPlex prepares for clinical feasibility study

RNS Number : 1676K

Barkby Group PLC (The)

20 April 2020

 

20 April 2020

The Barkby Group Plc

("Barkby or "The Group")

VivoPlex prepares for first clinical feasibility study of wireless uterine sensor

The Barkby Group PLC, the diversified business group, is pleased to announce that VivoPlex Group Ltd has received UK regulatory approval to initiate the first clinical feasibility study of its wireless battery-free uterine sensor system.

The study is expected to generate key clinical data to support European approval (CE marking) for VivoPlex's first product, which is part of a range of reproductive health biosensors it is developing. The approval for the study is an important milestone for VivoPlex in the path towards commercialisation of its intra-uterine sensing system.

In line with other medical device and pharmaceutical companies, the study will start as soon as practicably possible after clinical capacity becomes available post the COVID-19 pandemic.

Charles Dickson, Executive Chairman of the Barkby Group, commented:

"VivoPlex aims to transform fertility treatment for millions of people and I am delighted that it is one step closer to realising that aim, having received regulatory approval for its clinical feasibility study.  We are very excited by the business's potential to become a significant disruptor in the human fertility sector."

Contacts:

finnCap Ltd (Nomad and Broker)	[phone]
Carl Holmes/Simon Hicks (corporate finance) Tim Redfern/Richard Chambers (ECM)
Camarco (Financial PR)	[phone]
Jennifer Renwick/Jake Thomas

Notes to editors

The Barkby Group PLC is a diversified group of high growth, high quality businesses run by an entrepreneurial and experienced management team. The existing wholly owned businesses within Barkby include; Commercial Property Development, Barkby Life Sciences, Barkby Hospitality (comprising Barkby Pubs and Workshop Coffee) and Centurian Automotive. Barkby's strategy is to accelerate and maximise opportunities within its existing businesses as well as continue to source and invest in cash generative, growth businesses with the ability to disrupt.

 

END

 

 

NRAFIFVRSLIIFII